Go back to trials list
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Description
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax.This is an open-label, multi-center, dose-escalation, Phase 1 study of PRT2527, a CDK9 inhibitor, as monotherapy for participants with relapsed and refractory lymphoid and myeloid malignancies, in combination with zanubrutinib, a Bruton tyrosine kinase inhibitor (BTKi) for participants with lymphoid malignancies, or in combination with venetoclax, a B-cell lymphoma 2 inhibitor (BCL-2i) in participants with myeloid malignancies. The study will be conducted in two parts, the dose escalation phase and the dose confirmation phase for both monotherapy and combination therapy. The dose e
Trial Eligibility
Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures * Histologically or cytologically confirmed diagnosis of aggressive B-cell lymphoma subtypes, MCL, MZL, or CLL/SLL (including Richter's syndrome) based on local testing, or TCL (monotherapy only), AML, CMML, MDS, or MDS/MPN overlap syndrome that have relapsed or become refractory to or be ineligible for standard-of-care therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status of \< 2. * Adequate organ function (hematology, renal, and hepatic) * Echocardiogram (or multigated acquisition \[MUGA\] scan) indicating a left ventricular ejection fraction of ≥ 50% Exclusion Criteria: * Have active central nervous system involvement by malignancy, uncontrolled intercurrent illnesses, and active infections requiring systemic therapy * Have undergone HSCT within the last 90 days or have graft versus host disease (GvHD) Grade \> 1 at study entry * Have severe pulmonary disease with hypoxemia * History of another malignancy except for adequately treated non-melanoma skin cancer or lentigo maligna, superficial bladder cancer, and carcinoma in situ of the cervix without evidence of disease, and asymptomatic prostate cancer without known metastatic disease and no requirement for therapy * Concurrent treatment or within 15 days of starting study treatment with strong CYP3A4 inhibitors * Prior exposure to a CDK9 inhibitor * Wait at least 5 half-lives of the agent or 14 days after their investigational or approved therapies before start of study treatment, whichever is shorter * Mean corrected QT interval of \> 470 msec following triplicate ECG measurement or history of long QT syndrome * T-Cell leukemias
Study Info
Organization
Prelude Therapeutics
Primary Outcome
Dose limiting toxicity (DLT) of PRT2527
Interventions
Locations Recruiting
City of Hope
United States, California, Duarte
American Oncology Partners of Maryland, PA
United States, Maryland, Bethesda
Dana-Farber Cancer Institute
United States, Massachusetts, Boston
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
United States, New York, New York
University of Virginia Comprehensive Cancer Center
United States, Virginia, Charlottesville
Interested in joining this trial?
Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.
Get the latest thought leadership on your Juvenile Myelomonocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.